Tempus xE is a whole exome next-generation sequencing assay that analyzes the entire coding region (exome) of the patient’s genome, combined with whole transcriptome RNA sequencing. This is done as a tumor: normal matched assay with a tumor and normal specimens sequenced to an average depth of 250x and 150x, respectively. Whole transcriptome RNA-seq is 50 million reads. It encompasses 19,396 genes covering ~39 Mb of genomic space and is optimized for formalin fixed paraffin embedded (FFPE) tissue samples. The FFPE tumor tissue is matched to a normal blood or saliva sample to ensure fidelity of somatic variant calling. The xE assay identifies actionable oncogenic variants. From DNA sequencing, somatic and incidentally detected germline single nucleotide variants (SNVs), insertions and deletions (indels), and copy number variants (CNVs) are reported. From RNA-seq, gene fusions (translocations) are detected in an unbiased and comprehensive manner.
Next-Generation Sequencing (NGS)